124. AAV-Mediated Antisense Oligonucleotide-Based Therapy for CEP290-Associated LCA

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)35137-1
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Elsevier BV

Related search

Antisense Oligonucleotide Therapy for Neurodegenerative Disease

Journal of Clinical Investigation
Medicine
2006English

Antisense Oligonucleotide Gene Therapy for Neuromuscular Disorders

University of Ottawa Journal of Medicine
2018English

A Multi-Targeted Antisense Oligonucleotide-Based Therapy Directed at Phosphodiesterases 4 and 7 for COPD

2012English

Antisense Oligonucleotide Hope for Childhood Epilepsies

Nature Reviews Neurology
Molecular NeuroscienceNeurologyCellular
2020English

Antisense Oligonucleotide Treatment for Human Astrocytoma

Genome Biology
2001English

SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy

JAMA Neurology
Neurology
2013English

Legionella Pneumophila and Dendrimers-Mediated Antisense Therapy

Advanced Pharmaceutical Bulletin
ToxicologyPharmaceuticsPharmacologyPharmaceutical Science
2017English

Oligonucleotide-Based Gene Therapy for Cardiovascular Disease Are Oligonucleotide Therapeutics Novel Cardiovascular Drugs

Current Drug Targets
Molecular MedicineDrug DiscoveryClinical BiochemistryPharmacology
2000English

AAV-mediated Gene Transfer for Hemophilia

Genetics in Medicine
MedicineGenetics
2002English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy